In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Janssen and Shire get Waldheim's synthetic galanthamine

Executive Summary

J&J's Janssen Pharmaceutica and Shire Pharmaceuticals, partners in developing Shire's Phase III galanthamine Alzheimer's drug, licensed rights to a synthetic galanthamine called Nivalin from Austrian drugmaker Waldheim Pharmazeutika.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register